Biogen said on Friday it had either paused or discontinued funding for most of Apellis Pharmaceutica

[url="]Pfizer Inc. [/url](NYSE: PFE) today announced detailed progression-free and overall survival

[url="]Pfizer Inc. [/url](NYSE: PFE) today announced detailed results from the pivotal Phase 3 TALAP

Biogen shares slip after mixed Phase 2 Alzheimer's data, but analysts remain optimistic on diran

FDA extends review for Biogen's Leqembi Iqlik for early Alzheimer's disease to August 2026.

NEW YORK, May 7, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S

https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20260507-1483310/1483310_tph-apl

The headline numbers for Apellis Pharmaceuticals (APLS) give insight into how the company performed

Apellis Pharmaceuticals, Inc. (APLS) came out with quarterly earnings of $0.15 per share, beating th

NEW YORK, May 05, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & A

Stocks AVNS, APLS, and CERS in healthcare sector flashing warning to momentum-sensitive investors. H

The Nasdaq Composite surged 15.3% in April, marking its strongest monthly gain since the early pande

Biogen beats Q1 earnings and revenue estimates, fueled by new drug growth, but cuts 2026 EPS outlook

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following compan

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti,

NEW YORK, April 14, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde a

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following compan

Shares of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS - Get Free Report) have received an average re

Biogen partners with Alloy Therapeutics to advance antisense therapies using RNA-targeting technolog

MILWAUKEE, April 07, 2026 (GLOBE NEWSWIRE) -- Ademi LLP is investigating Apellis (NASDAQ: APLS) for

Apellis jumps as Biogen agrees $5.6 Billion acquisition, offering $41/share plus milestones, boostin

Apellis jumps as Biogen agrees $5.6 Billion acquisition, offering $41/share plus milestones, boostin

Major M&A deals this week include: Eli Lilly's $7.8 billion purchase of Centessa Pharmaceuti

Pre-Market Stock Futures: Risk-on appeared back, at least for the last two days, as the stock market

Shares of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS - Get Free Report) hit a new 52-week high duri

NEW YORK, April 1, 2026 /PRNewswire/ -- Class Action Attorney  Juan Monteverde  with Monteverde & As

BIIB's $5.6B offer to acquire APLS is set to add two key immunology drugs, boosting near-term revenu

Wall Street analysts changed outlook for top names. See all rating changes on analyst ratings page.

Top Wall Street analysts changed their outlook on top names. For a complete view of all rating chang

Apellis Pharmaceuticals (APLS) was a big mover last session on higher-than-average trading volume. T

US stocks rise on Tuesday, with NASDAQ up 2% and Dow up 1.37%. Communication services shares gain 2.

Apellis surges after Biogen's $5.6 billion buyout at $41 per share, adding complement therapies

US stocks rise, Dow Jones gains 600+ pts. Apellis Pharma shares surge 136.4% after buyout by Biogen

US stocks higher, Dow up 0.90%, Nasdaq up 1.61%. Communication services gained 1.8%, utilities fell

Acquisition will bring two differentiated commercialized immunology medicines to Biogen with EMPAVEL

Wall Street traded timidly on Tuesday despite another benign inflation report that reinforced expect

Gold and silver surged to fresh record highs Monday as investors reassessed the Federal Reserve'

The S&P 500 pushed to fresh record highs during midday trading on Wednesday, extending a three-d

U.S. stock futures were mixed this morning, with the Dow futures gaining around 0.1% on Friday.

Shares of Top KingWin Ltd (NASDAQ: WAI) rose sharply in pre-market trading after the company announc